Side-by-side · Research reference

RetatrutidevsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

Retatrutide

Testagen

Primary target

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Testicular tissue; proposed nuclear DNA interaction

Pathway

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

Retatrutide

Testagen

Standard dose

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

—

Frequency

Once weekly

Once daily or alternate days

Titration schedule

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

—

Evidence basis

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

Indefinite for chronic indication (presumed)

—

Reconstitution

Investigational; not commercially available

Sterile water or bacteriostatic saline

Timing

Any time of day

—

Half-life

~6 days (estimated from class)

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

04Side Effects & Safety

Parameter

Retatrutide

Testagen

GI symptoms

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

—

Heart rate

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

—

Glucose handling

Glycemic improvement; rare hyperglycemia from glucagon component

—

Pancreatitis risk

Class warning

—

Thyroid C-cell tumours

Class warning (presumed)

—

Pregnancy / OB

Avoid (insufficient data)

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Testagen

·Active testicular malignancy

Relative Contraindications

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

Retatrutide

Testagen

1. Reconstitution

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Once weekly, same day.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Refrigerate 2–8 °C. Light-protected.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

27–31G, 4–8 mm insulin syringe.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.